<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124448</url>
  </required_header>
  <id_info>
    <org_study_id>PROBIOLAC</org_study_id>
    <nct_id>NCT01124448</nct_id>
  </id_info>
  <brief_title>Global Effects of a Probiotic Strain on Lactating Women</brief_title>
  <acronym>PROBIOLAC</acronym>
  <official_title>Oral Administration of a Probiotic to Lactating Women: Microbiological, Immunological, Transcriptomics and Metabolomics Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Complutense de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Council, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danone Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Complutense de Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will try to confirm if application of probiotic strains
      isolated from breast milk actually have a beneficial effect on women suffering lactational
      mastitis. This project has been design to offer an integrated vision of the effects of
      probiotherapy (Lactobacillus salivarius PS2) on the human host. Therefore, the investigators
      propose a multidisciplinary approach involving the application of microbiological,
      immunological, genomic, metagenomic, transcriptomic and metabolomic techniques. The
      hypothesis is that probiotherapy will cause different effects on the host, and the objective
      is the finding of markers that may support the beneficial effect of the strain in such
      condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of Clinically Definite Mastitis Confirmed by Microbiological Cultures and Somatic Cell Counts</measure>
    <time_frame>one week</time_frame>
    <description>Total milk bacterial count at the end of the study (after probiotic administration for 21 days), measured as log10 of the number of colony-forming units per mL of milk</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evidence of Changes in Gene Expression of Somatic Cells Obtained From Milk Samples</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of Changes in the Metabolic Profile of Urine</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of Changes in the Macronutrient and Electrolyte Profiles of Milk</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of Changes in the Immunological Profile of Milk</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Mastitis</condition>
  <arm_group>
    <arm_group_label>Lactobacillus salivarius PS2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with mastitis (n=25) receiving Lactobacillus salivarius PS2 (9.5 log per day, 21 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactobacillus salivarius PS2B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactating women without mastitis (n=15)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lactobacillus salivarius PS2</intervention_name>
    <description>9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days</description>
    <arm_group_label>Lactobacillus salivarius PS2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lactobacillus salivarius PS2</intervention_name>
    <description>9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days</description>
    <arm_group_label>Lactobacillus salivarius PS2B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal term pregnancy

          -  Lactating women

          -  Healthy breastfed infant

        Women with mastitis:

          -  Clinical symptoms of mastitis

          -  Painful breastfeeding

          -  Count of staphylococci, streptococci and/or corynebacteria in milk higher than 3,000
             colony-forming units/mL

          -  Leukocyte count in milk higher 6 log10/mL

        Women without mastitis:

          -  No clinical symptoms of mastitis

          -  No painful breastfeeding

          -  Count of staphylococci, streptococci and/or corynebacteria in milk lower than 500
             colony-forming units/mL

          -  Leukocyte count in milk lower 5 log10/mL

        Exclusion Criteria:

          -  Allergy to cow's milk protein

          -  Intolerance to lactose

          -  Antibiotic treatment

          -  Breast abscess

          -  Raynaud syndrome

          -  Any parallel disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan M Rodríguez, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidad Complutense de Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dpt. Nutricion, Bromatologia y Tecnologia de los Alimentos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ucm.es/info/probilac/</url>
    <description>website of the research group</description>
  </link>
  <reference>
    <citation>Arroyo R, Martín V, Maldonado A, Jiménez E, Fernández L, Rodríguez JM. Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk. Clin Infect Dis. 2010 Jun 15;50(12):1551-8. doi: 10.1086/652763.</citation>
    <PMID>20455694</PMID>
  </reference>
  <reference>
    <citation>Jiménez E, Fernández L, Maldonado A, Martín R, Olivares M, Xaus J, Rodríguez JM. Oral administration of Lactobacillus strains isolated from breast milk as an alternative for the treatment of infectious mastitis during lactation. Appl Environ Microbiol. 2008 Aug;74(15):4650-5. doi: 10.1128/AEM.02599-07. Epub 2008 Jun 6.</citation>
    <PMID>18539795</PMID>
  </reference>
  <results_reference>
    <citation>Vázquez-Fresno R, Llorach R, Marinic J, Tulipani S, Garcia-Aloy M, Espinosa-Martos I, Jiménez E, Rodríguez JM, Andres-Lacueva C. Urinary metabolomic fingerprinting after consumption of a probiotic strain in women with mastitis. Pharmacol Res. 2014 Sep;87:160-5. doi: 10.1016/j.phrs.2014.05.010. Epub 2014 May 29.</citation>
    <PMID>24880136</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2010</study_first_submitted>
  <study_first_submitted_qc>May 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2010</study_first_posted>
  <results_first_submitted>July 3, 2014</results_first_submitted>
  <results_first_submitted_qc>August 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 20, 2014</results_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Complutense de Madrid</investigator_affiliation>
    <investigator_full_name>Juan M. Rodríguez</investigator_full_name>
    <investigator_title>Professor, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>TFF1 protein, human</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lactobacillus Salivarius PS2</title>
          <description>Women with mastitis (n=25) receiving Lactobacillus salivarius PS2 (9.5 log per day, 21 days)
Lactobacillus salivarius PS2: 9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days</description>
        </group>
        <group group_id="P2">
          <title>Lactobacillus Salivarius PS2B</title>
          <description>Lactating women without mastitis (n=15)
Lactobacillus salivarius PS2: 9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This study was designed to evaluate a high number of microbiological, biochemical or immunological parameters before and after the administration of a probiotic to women with mastitis and to elucidate which of them can be useful as biomarkers in future studies. The number of participants was considered suitable for such purpose.</population>
      <group_list>
        <group group_id="B1">
          <title>Lactobacillus Salivarius PS2</title>
          <description>Women with mastitis (n=25) receiving Lactobacillus salivarius PS2 (9.5 log per day, 21 days)
Lactobacillus salivarius PS2: 9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days</description>
        </group>
        <group group_id="B2">
          <title>Lactobacillus Salivarius PS2B</title>
          <description>Lactating women without mastitis (n=15)
Lactobacillus salivarius PS2: 9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="7.7"/>
                    <measurement group_id="B2" value="29.0" spread="7.8"/>
                    <measurement group_id="B3" value="28.6" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total milk bacterial count (initial)</title>
          <units>log10 CFU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.08" spread="0.20"/>
                    <measurement group_id="B2" value="3.19" spread="0.59"/>
                    <measurement group_id="B3" value="3.63" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evidence of Clinically Definite Mastitis Confirmed by Microbiological Cultures and Somatic Cell Counts</title>
        <description>Total milk bacterial count at the end of the study (after probiotic administration for 21 days), measured as log10 of the number of colony-forming units per mL of milk</description>
        <time_frame>one week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Salivarius PS2</title>
            <description>Women with mastitis (n=25) receiving Lactobacillus salivarius PS2 (9.5 log per day, 21 days)
Lactobacillus salivarius PS2: 9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Lactobacillus Salivarius PS2B</title>
            <description>Lactating women without mastitis (n=15)
Lactobacillus salivarius PS2: 9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days</description>
          </group>
        </group_list>
        <measure>
          <title>Evidence of Clinically Definite Mastitis Confirmed by Microbiological Cultures and Somatic Cell Counts</title>
          <description>Total milk bacterial count at the end of the study (after probiotic administration for 21 days), measured as log10 of the number of colony-forming units per mL of milk</description>
          <units>log10 CFU/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" lower_limit="2.90" upper_limit="3.28"/>
                    <measurement group_id="O2" value="2.90" lower_limit="2.12" upper_limit="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evidence of Changes in Gene Expression of Somatic Cells Obtained From Milk Samples</title>
        <time_frame>one year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evidence of Changes in the Metabolic Profile of Urine</title>
        <time_frame>One year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evidence of Changes in the Macronutrient and Electrolyte Profiles of Milk</title>
        <time_frame>One year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evidence of Changes in the Immunological Profile of Milk</title>
        <time_frame>one year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lactobacillus Salivarius PS2</title>
          <description>Women with mastitis (n=25) receiving Lactobacillus salivarius PS2 (9.5 log per day, 21 days)
Lactobacillus salivarius PS2: 9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days</description>
        </group>
        <group group_id="E2">
          <title>Lactobacillus Salivarius PS2B</title>
          <description>Lactating women without mastitis (n=15)
Lactobacillus salivarius PS2: 9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Juan M Rodríguez</name_or_title>
      <organization>Complutense University Madrid</organization>
      <phone>34 91 3943837</phone>
      <email>jmrodrig@vet.ucm.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

